中国肿瘤临床
中國腫瘤臨床
중국종류림상
CHINESE JOURNAL OF CLINICAL ONCOLOGY
2013年
15期
898-901
,共4页
李莉%刘志武%谭榜云%陈明%张艺
李莉%劉誌武%譚榜雲%陳明%張藝
리리%류지무%담방운%진명%장예
破骨细胞分化因子%破骨细胞生成抑制因子%肺癌%骨转移
破骨細胞分化因子%破骨細胞生成抑製因子%肺癌%骨轉移
파골세포분화인자%파골세포생성억제인자%폐암%골전이
osteoclast differentiation factor%osteo-clastogenesis inhibitory factor%lung cancer%bone metastases
目的：探讨检测破骨细胞分化因子（osteoclast differentiation factor，ODF）和破骨细胞生成抑制因子（osteo-clastogenesis inhibitory factor，OCIF）对肺癌骨转移诊断及病情评价的临床价值。方法：分析2009年7月至2012年4月186例初诊为肺癌患者的资料。肺癌骨转移组和非骨转移组分别为104例和82例，采用ELISA法测定各组血清ODF和OCIF浓度。结果：骨转移组患者血清ODF和OCIF分别为（32.22±6.22）ng/L、（41.23±8.13）ng/L，明显高于非骨转移组的（8.35±5.42）ng/L、（10.15±4.42）ng/L，有显著性差异（P<0.01）。ODF和OCIF诊断肺癌骨转移ROC曲线下面积分别为0.91和0.87，具有良好的诊断价值。诊断肺癌骨转移的灵敏度、特异度，ODF分别为90.38%、86.59%；OCIF分别为86.54%、84.15%。ODF随骨转移部位数量增加而明显升高，OCIF随骨转移部位数量增加而明显降低。新发骨转移组和骨转移组血清ODF和OCIF浓度均显著高于非骨转移组，有显著性差异（P<0.01）；新发骨转移组血清ODF和OCIF浓度与骨转移组比较，两组间无显著性差异（P>0.05）。结论：肺癌患者发生骨转移时，血清ODF和OCIF含量明显增高，可作为判断肺癌患者骨转移及监测病情的参考指标，在临床上有广泛的应用前景。
目的：探討檢測破骨細胞分化因子（osteoclast differentiation factor，ODF）和破骨細胞生成抑製因子（osteo-clastogenesis inhibitory factor，OCIF）對肺癌骨轉移診斷及病情評價的臨床價值。方法：分析2009年7月至2012年4月186例初診為肺癌患者的資料。肺癌骨轉移組和非骨轉移組分彆為104例和82例，採用ELISA法測定各組血清ODF和OCIF濃度。結果：骨轉移組患者血清ODF和OCIF分彆為（32.22±6.22）ng/L、（41.23±8.13）ng/L，明顯高于非骨轉移組的（8.35±5.42）ng/L、（10.15±4.42）ng/L，有顯著性差異（P<0.01）。ODF和OCIF診斷肺癌骨轉移ROC麯線下麵積分彆為0.91和0.87，具有良好的診斷價值。診斷肺癌骨轉移的靈敏度、特異度，ODF分彆為90.38%、86.59%；OCIF分彆為86.54%、84.15%。ODF隨骨轉移部位數量增加而明顯升高，OCIF隨骨轉移部位數量增加而明顯降低。新髮骨轉移組和骨轉移組血清ODF和OCIF濃度均顯著高于非骨轉移組，有顯著性差異（P<0.01）；新髮骨轉移組血清ODF和OCIF濃度與骨轉移組比較，兩組間無顯著性差異（P>0.05）。結論：肺癌患者髮生骨轉移時，血清ODF和OCIF含量明顯增高，可作為判斷肺癌患者骨轉移及鑑測病情的參攷指標，在臨床上有廣汎的應用前景。
목적：탐토검측파골세포분화인자（osteoclast differentiation factor，ODF）화파골세포생성억제인자（osteo-clastogenesis inhibitory factor，OCIF）대폐암골전이진단급병정평개적림상개치。방법：분석2009년7월지2012년4월186례초진위폐암환자적자료。폐암골전이조화비골전이조분별위104례화82례，채용ELISA법측정각조혈청ODF화OCIF농도。결과：골전이조환자혈청ODF화OCIF분별위（32.22±6.22）ng/L、（41.23±8.13）ng/L，명현고우비골전이조적（8.35±5.42）ng/L、（10.15±4.42）ng/L，유현저성차이（P<0.01）。ODF화OCIF진단폐암골전이ROC곡선하면적분별위0.91화0.87，구유량호적진단개치。진단폐암골전이적령민도、특이도，ODF분별위90.38%、86.59%；OCIF분별위86.54%、84.15%。ODF수골전이부위수량증가이명현승고，OCIF수골전이부위수량증가이명현강저。신발골전이조화골전이조혈청ODF화OCIF농도균현저고우비골전이조，유현저성차이（P<0.01）；신발골전이조혈청ODF화OCIF농도여골전이조비교，량조간무현저성차이（P>0.05）。결론：폐암환자발생골전이시，혈청ODF화OCIF함량명현증고，가작위판단폐암환자골전이급감측병정적삼고지표，재림상상유엄범적응용전경。
Objective:This study was aimed to investigate the value of osteoclast differentiation factor (ODF) and osteoclastogen-esis inhibitory factor (OCIF) detection for clinical diagnosis and assessment of patient condition in bone metastasis of lung cancer. Methods:Data from 186 lung cancer patients who were preliminary diagnosed between July 2009 and April 2012 were analyzed. Cas-es were divided into the bone metastasis group with 82 cases (group A) and the non-bone metastasis group with 104 cases (group B). Concentrations of serum ODF and OCIF in each group were detected by ELISA. Results: ODF and OCIF values of group A were (32.22±6.22) ng/L and (41.23±8.13) ng/L, respectively, which were significantly higher than the corresponding values in group B [(8.35 ±5.42) ng/L and (10.15±4.42) ng/L]. The differences between the two groups were statistically significant (P<0.01). Areas under the re-ceiver operating characteristic curves of ODF and OCIF, which are used to diagnose bone metastasis in lung cancer, were 0.91 and 0.87, respectively, manifesting good diagnostic value. The sensitivity and specificity of ODF in diagnosing lung cancer with bone metastasis were 90.38%and 86.59%, respectively, and those of OCIF were 86.54%and 84.15%, respectively. ODF increased, whereas OCIF de-creased significantly, with increasing bone metastasis. ODF and OCIF concentrations in group A and the group with newly-found bone metastasis were significantly higher than those in group B, with statistically significant differences among these groups (P<0.01). Com-pared with group A, less difference was found in the ODF and OCIF of newly-found bone metastases, without statistical significance be-tween these groups (P>0.05). Conclusion:The serum ODF and OCIF concentrations significantly increase when bone metastasis oc-curs in lung cancer patients. Hence, these variables are useful as indices for monitoring bone metastases and evaluating patient condi-tion. An extensive application prospect is proposed.
